| 3.26 0.16 (5.16%) | 07-26 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 4.2 |
1-year : | 4.91 |
| Resists | First : | 3.59 |
Second : | 4.2 |
| Pivot price | 3.07 |
|||
| Supports | First : | 3.01 |
Second : | 2.65 |
| MAs | MA(5) : | 3.09 |
MA(20) : | 3 |
| MA(100) : | 3.8  |
MA(250) : | 4.57 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 49.8 |
D(3) : | 45 |
| RSI | RSI(14): 54.8 |
|||
| 52-week | High : | 7.84 | Low : | 2.65 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ ABCL ] has closed below upper band by 27.1%. Bollinger Bands are 9.2% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 3.28 - 3.3 | 3.3 - 3.31 |
| Low: | 3.11 - 3.13 | 3.13 - 3.14 |
| Close: | 3.24 - 3.26 | 3.26 - 3.28 |
AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, artificial intelligence-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that could be developed as drugs. As of December 31, 2021, the company had 156 discovery programs that are either completed, in progress, or under contract with 36 partners. AbCellera Biologics Inc. has a research collaboration and license agreement with Eli Lilly and Company. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.
Mon, 22 Jul 2024
Equities Analysts Offer Predictions for AbCellera Biologics Inc.'s Q3 2024 Earnings (NASDAQ:ABCL) - MarketBeat
Mon, 22 Jul 2024
Leerink Partnrs Analysts Decrease Earnings Estimates for AbCellera Biologics Inc. (NASDAQ:ABCL) - Defense World
Sat, 20 Jul 2024
Mirae Asset Global Investments Co. Ltd. Makes New Investment in AbCellera Biologics Inc. (NASDAQ:ABCL) - Defense World
Sat, 20 Jul 2024
Mirae Asset Global Investments Co. Ltd. Buys Shares of 100,145 AbCellera Biologics Inc. (NASDAQ:ABCL) - American Banking and Market News
Fri, 12 Jul 2024
Possible Turnaround For AbCellera Biologics Insiders, Still Down US$203k - Simply Wall St
Tue, 09 Jul 2024
AbCellera Biologics (ABCL) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 294 (M) |
| Shares Float | 188 (M) |
| Held by Insiders | 28 (%) |
| Held by Institutions | 43.8 (%) |
| Shares Short | 18,780 (K) |
| Shares Short P.Month | 18,420 (K) |
| EPS | -0.51 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.84 |
| Profit Margin | 0 % |
| Operating Margin | -551.5 % |
| Return on Assets (ttm) | -9.6 % |
| Return on Equity (ttm) | -12.6 % |
| Qtrly Rev. Growth | -18.4 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0.12 |
| EBITDA (p.s.) | -0.7 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -42 (M) |
| Levered Free Cash Flow | -88 (M) |
| PE Ratio | -6.4 |
| PEG Ratio | -0.6 |
| Price to Book value | 0.84 |
| Price to Sales | 26.78 |
| Price to Cash Flow | -23.09 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|